8-K: Spruce Biosciences Reports Strong Q2, Advances Rare Disease Therapy

Spruce Biosciences announced positive long-term clinical data for its Sanfilippo Syndrome Type B therapy, Tralesinidase Alfa, and initiated a Phase 2 trial for Major Depressive Disorder, alongside its second quarter 2025 financial results.

Summary

• Spruce Biosciences reported financial results for the second quarter ended June 30, 2025, and provided corporate updates.
• Integrated long-term clinical data for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) demonstrated profound and durable efficacy and safety over a five-year period.
• TA-ERT significantly reduced cerebral spinal fluid heparan-sulfate non-reducing end (CSF HS-NRE) levels by 91.5 ng/mL from baseline at 240 weeks (95% CI: -102.10, -80.90; p<0.0001).
• Cognition in the TA-ERT treated group remained stable, with Bayley-III Cognitive Raw Score (BSID-C) significantly higher than untreated, age-matched children (e.g., 34.66 difference at 10 years of age, p<0.0001).
• TA-ERT therapy was associated with stabilization of cortical grey matter volume (CGMV) after initial clearance, contrasting with decline in untreated children.
• The company anticipates submitting a Biologics License Application (BLA) for TA-ERT for MPS IIIB in the first quarter of 2026 under the accelerated approval pathway.
• The first patient was dosed in the Phase 2 TAMARIND trial of tildacerfont for Major Depressive Disorder (MDD), with topline results expected in the first half of 2026.
• Spruce implemented a 1-for-75 reverse stock split on August 7, 2025, and anticipates relisting on the Nasdaq Capital Market upon compliance with the minimum bid price for 20 consecutive trading days.
• Cash and cash equivalents were $16.4 million as of June 30, 2025, expected to fund operations through the end of 2025.
• Net loss for the second quarter of 2025 was $2.1 million, a significant reduction from $9.2 million in the same period of 2024.
• Research and Development (R&D) expenses for Q2 2025 were $(0.4) million, reflecting a reduction in recorded liabilities and an increase in receivables related to the TA-ERT acquisition.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to compelling long-term clinical data for TA-ERT, which addresses a significant unmet medical need and has potential for accelerated approval. Progress on the MDD program and efforts to relist on Nasdaq are also strong positives. While the cash runway is short, the clinical advancements and reduced net loss outweigh this concern in the immediate term, suggesting strong operational execution and potential for future value creation.

Positives

• Integrated long-term clinical data for TA-ERT in MPS IIIB demonstrated profound and durable efficacy, including significant reduction in CSF HS-NRE levels and stabilization of cognition and cortical grey matter volume.
• TA-ERT has shown an adequate safety profile over up to 7.3 years of exposure in a serious and fatal disease with no current treatment.
• Anticipated Biologics License Application (BLA) submission for TA-ERT in Q1 2026 under accelerated approval pathway positions it as a potential first-to-market and first disease-modifying therapy for MPS IIIB.
• First patient dosed in the Phase 2 TAMARIND trial of tildacerfont for MDD, advancing a new program targeting a biologically distinct subtype of MDD.
• Net loss significantly decreased to $2.1 million in Q2 2025 from $9.2 million in Q2 2024, indicating improved financial performance.
• Total operating expenses decreased to $2.7 million in Q2 2025 from $11.6 million in Q2 2024.
• Research and Development expenses were a credit of $(0.4) million in Q2 2025, primarily due to a reduction in recorded liabilities and an increase in receivables associated with the TA-ERT acquisition.
• Efforts to relist on the Nasdaq Capital Market are underway following a 1-for-75 reverse stock split, aiming to improve market visibility and liquidity.

Negatives

• Cash and cash equivalents decreased to $16.4 million as of June 30, 2025, from $38.8 million as of December 31, 2024.
• Cash and cash equivalents are only expected to fund the current operating plan through the end of 2025, indicating a short cash runway.
• No collaboration revenue was reported for the three and six months ended June 30, 2025, compared to $1.61 million and $3.612 million for the same periods in 2024.

Risks

• The ability to seek accelerated approval of TA-ERT for MPS IIIB based on existing clinical data is subject to regulatory discretion.
• The timing and likelihood of regulatory filings and approvals for TA-ERT, including the anticipated BLA submission, are uncertain.
• There is no guarantee that topline results from the TAMARIND study will be available in the first half of 2026 as anticipated.
• Resumption of trading on the Nasdaq Capital Market is contingent on maintaining compliance with the minimum bid price requirement for 20 consecutive trading days.
• General risks and uncertainties associated with the company's business, including the impact of geopolitical and macroeconomic events, could affect operations and financial results.

Future Outlook

The company anticipates submitting a Biologics License Application (BLA) for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) in the first quarter of 2026 under the accelerated approval pathway. Topline results from the Phase 2 TAMARIND study of tildacerfont for Major Depressive Disorder (MDD) are expected in the first half of 2026. The company also expects to resume trading on the Nasdaq Capital Market once it complies with the minimum bid price requirement for 20 consecutive trading days.

Management Comments

• "We remain steadfast in our efforts to advance TA-ERT as a potential first-to-market treatment for children diagnosed with Sanfilippo Syndrome Type B (MPS IIIB). We have a strong sense of urgency to deliver on our commitment to patients and families suffering with MPS IIIB and remain on track to submit the biologics license application under the accelerated approval pathway in the first quarter of 2026."
• "The integrated long-term clinical data of TA-ERT reinforces its potentially transformative clinical impact and compelling value proposition. TA-ERT has the potential to be the first disease-modifying therapy to treat MPS IIIB and could provide a novel option for families impacted by this devastating condition."

Industry Context

This announcement highlights significant progress in addressing severe unmet medical needs in rare neurological disorders, specifically Sanfilippo Syndrome Type B, where no approved treatments currently exist. The potential for TA-ERT to be a first-in-class, disease-modifying therapy positions Spruce Biosciences as a leader in this niche. Additionally, the initiation of the tildacerfont trial for Major Depressive Disorder, utilizing a proprietary genetic test to identify a specific patient subtype, aligns with the broader industry trend towards personalized medicine and targeted therapies in psychiatry, aiming to improve response rates in complex conditions.

Comparison to Industry Standards

• For Sanfilippo Syndrome Type B (MPS IIIB), TA-ERT is positioned as a potential first-in-class, disease-modifying therapy, as the filing explicitly states there is currently no treatment available for this serious and fatal disease. This lack of existing therapies means direct comparative benchmarks are absent, underscoring the high unmet medical need and the potential for TA-ERT to set a new standard of care.
• The clinical data for TA-ERT, demonstrating significant reduction in CSF HS-NRE and stabilization of cognition and CGMV over five years, represents a profound clinical impact in a neurodegenerative condition where untreated patients show progressive decline. This level of efficacy and durability is highly favorable given the severity of MPS IIIB.
• For Major Depressive Disorder (MDD), the Phase 2 TAMARIND study of tildacerfont, which utilizes HMNC's Cortibon genetic test to screen patients for hypothalamic-pituitary-adrenal (HPA) axis dysregulation, represents an innovative approach. This strategy aligns with the industry's move towards precision medicine in psychiatry, aiming to identify patient populations more likely to respond to specific mechanisms of action, potentially leading to higher efficacy rates compared to broad-spectrum antidepressants.

Stakeholder Impact

• **Patients and Families:** Potential for a first-in-class, disease-modifying therapy (TA-ERT) for Sanfilippo Syndrome Type B, a severe and fatal neurological disorder with no current treatment, offering significant hope.
• **Shareholders:** Positive clinical data and progress towards Nasdaq relisting could lead to increased share price and liquidity. However, the short cash runway implies potential future dilution from capital raises.
• **Employees:** Continued advancement of clinical programs and efforts to improve financial standing support ongoing operations and job security.
• **Investment Professionals:** Provides critical data for valuation and investment decisions, particularly regarding the high-potential TA-ERT program and the strategic move towards Nasdaq relisting.

Next Steps

• Submit Biologics License Application (BLA) for TA-ERT for MPS IIIB in Q1 2026.
• Anticipate topline results from the Phase 2 TAMARIND study of tildacerfont for MDD in 1H 2026.
• Achieve compliance with Nasdaq's minimum bid price requirement for 20 consecutive trading days to resume trading on the Nasdaq Capital Market.

Key Dates

Recommendation

The filing presents exceptionally strong long-term clinical data for TA-ERT in Sanfilippo Syndrome Type B, a devastating disease with no current treatment. This positions TA-ERT as a potential first-in-class, disease-modifying therapy with a clear path to accelerated approval in Q1 2026. Such a breakthrough in a high unmet medical need area carries significant market potential. Coupled with a substantial reduction in net loss and operating expenses, and active steps towards Nasdaq relisting, the company demonstrates strong operational execution and strategic focus. While the cash runway is limited to the end of 2025, the compelling clinical efficacy and regulatory progress for TA-ERT significantly de-risk the primary asset and are likely to attract future capital. This combination of scientific breakthrough, financial improvement, and market access initiatives makes Spruce Biosciences a compelling 'strong buy' for investors seeking high growth potential in the biotech sector.

Keywords

Biopharmaceutical, Sanfilippo Syndrome Type B, MPS IIIB, Tralesinidase Alfa, TA-ERT, Enzyme Replacement Therapy, Major Depressive Disorder, MDD, Tildacerfont, CRF1 receptor, Clinical Trials, Rare Disease, Neurological Disorders, Nasdaq Relisting, Biologics License Application, Accelerated Approval